Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.
Investors are optimistic about Penumbra (PEN) on strength exhibited in the Thrombectomy business and global expansion.
Penumbra (PEN) expects to materially increase both revenues and profitability in the company's international business in the next three years and beyond.